肾小管标志蛋白与肾病综合征疗效的关系  

The Relationship Between Renal Tubular Marker Protein and Nephrotic Syndrome

作　　者：刘孝猛[1] 刘劲松[1] 李萌[1] 刘丽颖[1] LIU Xiaomeng LIU Jinsong LI Meng LIU Liying(Nephrology Department, Heilongjiang Hospital, Harbin Heilongjiang 150036, China)

机构地区：[1]黑龙江省医院肾内科,黑龙江哈尔滨150036

出　　处：《中国继续医学教育》2017年第9期70-71,共2页China Continuing Medical Education

摘　　要：目的探讨肾小管标志蛋白和肾病综合征疗效之间的关系。方法研究时间为2014年5月—2016年12月,共选择患者91例,经临床确诊均为肾病综合征,所得数据记疾病组,对患者尿液中肾小管标志蛋白的含量进行测量,根据肾小管标志蛋白是否增加进行分组,同时采取强的松联合环磷酰胺治疗方案,记录两类患者治疗效果。在同一时段选择50例健康体检者,同样对其尿液肾小管标志蛋白进行测量,所得数据记健康组。结果疾病组患者β_2微球蛋白含量为(2.61±0.37)ml/L,高于健康组(0.20±0.08)ml/L(P<0.05)。标志蛋白增高组患者治疗总有效率为57.14%(36/63),低于未增高组92.86%(26/28)(P<0.05)。结论肾小管标志蛋白增高会降低肾病综合征治疗效果。Objective To investigate the relationship between renal tubular marker protein and nephrotie syndrome. Methods From May 2014 to December 2016, a total of 91 patients, diagnosed by clinical were nephrotic syndrome, the data on disease group, protein content were measured in urine of patients with renal tubular marked renal tubular marker proteins, according to whether to increase aregrouped, while taking prednisone and cyclophosphamide treatment, record two the effect of treatment in patients with class. At the same time, 50 healthy persons were selected to measure the renal tubular marker protein. Results The level of β2 in patients with disease was （2.61±0.37） ml/L, which was higher than that in healthy group （0.20±0.08） ml/L （P 〈 0.05）. The total effective rate of the treatment group was 57.14% （36/63）, which was lower than that of the non elevated group 92.86% （26/28） （P 〈 0.05）. Conclusion The increase of renal tubular marker protein may reduce the therapeutic effect of nephrotic syndrome.

关 键 词：肾病综合征 肾小管标志蛋白 疗效 

分 类 号：R692[医药卫生—泌尿科学]